A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2017
At a glance
- Drugs VCL HB01 (Primary)
- Indications Herpes genitalis; Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- Sponsors Vical
- 23 Oct 2017 According to the Vical media release, Following the 4th vaccination, each subject entered a 12-month surveillance period during which each new lesion recurrence is assessed in the clinic by the investigator. Once all subjects have completed a minimum of 9-months of surveillance, the primary endpoint of annualized recurrence rate will be calculated based on those recurrences that are both clinically- and virologically-confirmed.
- 19 Apr 2017 Status changed from recruiting to active, no longer recruiting, according to a Vical Inc. media release.
- 09 Mar 2017 According to the Vical media release, company expects the top-line data to be available in the second quarter of 2018.